Sinovac corrects Form 20-F note numbering

Sinovac Biotech Ltd. filed this Form 6-K to correct a typographical error in Note 2 of its Form 20-F for the year ended December 31, 2024.

Accepted by SEC EDGAR 05/07/2026 - 07:05 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Sinovac Biotech Ltd. filed this Form 6-K to correct a typographical error in Note 2 of its Form 20-F for the year ended December 31, 2024. The first-level subparagraphs in Note 2 on pages F-13 and F-14 were incorrectly numbered 1 through 10 and are now correctly designated A through J to match the related tables on pages F-15, F-16, F-18, F-19, F-21 and F-22. No changes are being made to the company’s financial statements or any other disclosures, and the annual report continues to speak as of the original April 30, 2026 filing date.

Key Terms

Form 6-K, Form 20-F, foreign private issuer, Consolidated Financial Statements, +1 more

5 terms

Form 6-K regulatory

"This current report on Form 6-K is furnished solely to correct a typographical error"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Form 20-F regulatory

"filed its annual report on Form 20-F for the fiscal year ended December 31, 2024"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Consolidated Financial Statements financial

"Note 2 to the Consolidated Financial Statements included in the Annual Report"

Consolidated financial statements combine the financial results of a parent company and all the companies it controls into one set of reports, like showing the whole family’s budget instead of each person’s separate accounts. For investors this matters because it gives a complete picture of assets, debts, revenue and cash flow across the entire group, helping assess true size, risk and profitability without missing or double-counting related activity.

incorporated by reference regulatory

"This current report is incorporated by reference into the Annual Report"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sinovac Biotech Ltd. (SVA) change in this Form 6-K?

Sinovac corrected a typographical error in Note 2 of its Form 20-F. The first-level subparagraphs were misnumbered 1–10 and are now properly labeled A–J to align with related tables in the consolidated financial statements.

Does this Sinovac (SVA) Form 6-K change any 2024 financial statements?

No, the filing states there are no revisions to the company’s financial statements. Only the subparagraph designations in Note 2 were corrected, with all underlying financial data and other disclosures left unchanged from the original Form 20-F.

Which part of Sinovac’s 2024 Form 20-F was affected by the correction?

The correction applies to Note 2 to the Consolidated Financial Statements. On pages F-13 and F-14, the first-level subparagraphs are now designated A through J, matching the tables in Note 2 on pages F-15, F-16, F-18, F-19, F-21 and F-22.

Does this Form 6-K update events after the original 20-F filing date for SVA?

No, the company states this filing does not reflect events after the April 30, 2026 initial filing date. The annual report, as corrected for the typographical error, continues to speak as of that original date without new event disclosures.

How is this Sinovac Form 6-K related to its Form 20-F?

The Form 6-K is incorporated by reference into the Form 20-F annual report. It serves solely to correct the subparagraph labeling in Note 2, ensuring consistency between narrative sections and the corresponding tables within the consolidated financial statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-32371

SINOVAC BIOTECH LTD.

No. 39 Shangdi Xi Rd, Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒          Form 40-F ☐

EXPLANATORY NOTE

On April 30, 2026 (the “Initial Filing Date”), Sinovac Biotech Ltd. (the “Company”) filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “Commission”) (File No. 001-32371).

This current report on Form 6-K is furnished solely to correct a typographical error in the sub-numbering of Note 2 to the Consolidated Financial Statements included in the Annual Report (“Note 2”). Specifically, on pages F-13 and F-14 of the Annual Report, the first-level subparagraphs in Note 2 were inadvertently numbered “1” through “10” instead of lettered “A” through “J,” as correctly referenced in the corresponding tables in Note 2 on pages F-15, F-16, F-18, F-19, F-21 and F-22 of the Annual Report. The correct first-level sub-paragraph designations should read “A” through “J.”

Other than the correction of this inadvertent typographical error in Note 2, this current report does not amend, update or restate any other information in the Annual Report and does not reflect events occurring after the Initial Filing Date. No revisions are being made to the Company’s financial statements or any other disclosure contained in the Annual Report.

The Annual Report, as corrected hereby, continues to speak as of the Initial Filing Date.

This current report is incorporated by reference into the Annual Report.

1 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SINOVAC BIOTECH LTD.
	By:	/s/ Nan Wang
	Name:	Nan Wang
	Title:	Chief Financial Officer

Date: May 7, 2026

2